Get the Stockscreener App
2.46
21.18%
0.43
Gt Biopharma Inc stock is traded at $2.46, with a volume of 26.64M.
It is up +21.18% in the last 24 hours and up +1.65% over the past month.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
See More
Previous Close:
$2.03
Open:
$2.46
24h Volume:
26.64M
Relative Volume:
32.28
Market Cap:
$5.50M
Revenue:
-
Net Income/Loss:
$-9.64M
P/E Ratio:
-0.3553
EPS:
-6.9236
Net Cash Flow:
$-10.11M
1W Performance:
+17.14%
1M Performance:
+1.65%
6M Performance:
+13.36%
1Y Performance:
-36.43%
1-Day Range:
$2.02
$3.12
1-Week Range:
$2.02
$3.12
52-Week Range:
$1.72
$10.66
Gt Biopharma Inc Stock (GTBP) Company Profile
Name
Gt Biopharma Inc
Sector
Industry
Phone
(800) 304-9888
Address
315 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
0.1935 | 408.35M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.50 | 372.90M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
0.4399 | 278.60M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.79 | 120.14M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
4.0439 | 52.60M | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Initiated | ROTH MKM | Buy |
| May-24-21 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | B. Riley Securities | Buy |
| Mar-17-21 | Initiated | ROTH Capital | Buy |
Gt Biopharma Inc Stock (GTBP) Latest News
GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak - Asianet Newsable
"Signal Advance, Inc. (OTC: SIGL) Achieves Technology - openPR
GT Biopharma announces warrant exercise, plans new offering - Investing.com
GT Biopharma announces warrant exercise, plans new offering By Investing.com - Investing.com UK
GT Biopharma Announces Exercise of Warrants - GlobeNewswire
GT Biopharma's Financial Maneuver: $0.7M Cash Influx Comes With 604K New Warrants - StockTitan
Stock market today: Wah Fu Education Group +219.55%, Jet.AI +46.26% among top gainers in early trading - Business Upturn
Artificial Intelligence (AI) News Live Feed - StockTitan
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement - The Manila Times
GT Biopharma withdraws SEC registration statement - Investing.com
GT Biopharma Pulls Back S-1 Filing: What Does This Mean for Their Financing Strategy? - StockTitan
GT Biopharma, Inc. SEC 10-K Report - TradingView
This New Nasdaq Biotech Could Revolutionize Emergency Cardiac CareHere's Why - StockTitan
Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Expands By 5.1% - Defense World
Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Set To Breakeven - Yahoo Finance
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
GT Biopharma Announces Recently Presented Data on Our Next Generation TriKE (OXS-C3550) at The Ash Meeting in Atlanta, GA - ACCESS Newswire
Nanobodies Market Analysis: Growth Drivers in Targeted - openPR
Pre-market Movers In Healthcare Sector: HUGE, ONTX, SVRA, CELC, CHFS... - RTTNews
StockNews.com Initiates Coverage on Beasley Broadcast Group (NASDAQ:BBGI) - Defense World
StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS) - Defense World
Barnes Group (NYSE:B) Now Covered by StockNews.com - Defense World
Apollo Commercial Real Estate Finance (NYSE:ARI) Stock Rating Lowered by StockNews.com - Defense World
KULR Technology Group Announces Strategic Partnership with EDOM Technology - Defense World
StockNews.com Begins Coverage on Power REIT (NYSE:PW) - Defense World
Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com - Defense World
Embrace Change Acquisition Corp. Enters Definitive Merger Agreement with Tianji for Public ListingSAN DIEGO, CA – January 27, 2025 – Embrace Change Acquisition Corp. (NASDAQ: EMCGU), a special purpose acquisition company, and Tianji Tire Global - Defense World
Goldman Sachs Announces Adoption of Tax Benefit Preservation Plan - Defense World
First Financial Bancorp Reports Solid Financial Performance in Fourth Quarter 2024 - Defense World
Seaport Res Ptn Forecasts Weaker Earnings for Sands China - Defense World
Galectin Therapeutics Inc. Reports Results from 2024 Annual Meeting in Recent 8-K Filing - Defense World
Cormark Weighs in on Real Matters’ FY2025 Earnings (TSE:REA) - Defense World
AmpliTech Group, Inc. (NASDAQ:AMPG) Short Interest Down 60.9% in January - Defense World
GT Biopharma Announces First Patient Dosed in Phase 1 Trial - GlobeNewswire
GT Biopharma Announces Expanded TriKE(TM) Partnership With Cytovance Biologics - ACCESS Newswire
GT Biopharma, Inc. Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies - Marketscreener.com
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies - The Manila Times
GT Biopharma Initiates Phase 1 Trial of Advanced TriKE Therapy for Blood Cancers - StockTitan
GT Biopharma Provides Update Concerning Trike(TM) Drug Development Programs and Other Strategic Initiatives - ACCESS Newswire
GT Biopharma Announces Completion of $5.6 Million Bridge Financing - ACCESS Newswire
GT Biopharma Announces Dr. Greg Berk, M.D. Joins Board of Directors - ACCESS Newswire
UPDATE: GT Biopharma Announces Preliminary Results for GTB-3550 TriKE(TM) Phase I/II Clinical Trial for Treatment of Acute Myeloid Leukemia - ACCESS Newswire
GT Biopharma Hires Chief Medical Officer Jeffery Miller, M.D. - ACCESS Newswire
GT Biopharma and Cytovance Biologics Announce Collaboration Agreement TriKE(TM) Therapeutic for Treatment of Coronavirus Infection - ACCESS Newswire
GT Biopharma Announces Preliminary Results for GTB-3550 TriKE(TM) Phase I/II Clinical Trial for Treatment of Acute Myeloid Leukemia - ACCESS Newswire
Nanobodies Market Generated Opportunities, Future Scope - openPR
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews
Roche to complete $1.5 billion acquisition of U.S. biopharma company Poseida - Yahoo Finance
Nanobodies Market reached US$ 502.60 million in 2023 and - openPR
Gt Biopharma Inc Stock (GTBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):